Sarosdy M F, Lamm D L
Division of Urology, University of Texas Health Science Center, San Antonio.
J Urol. 1989 Sep;142(3):719-22. doi: 10.1016/s0022-5347(17)38865-1.
Between January 1978 and February 1984, 120 patients with superficial bladder tumors and/or carcinoma in situ were enrolled in previously reported therapeutic trials of bacillus Calmette-Guerin. Of all treated patients 78 per cent responded to initial therapy, with a followup of 13 to 120 months (median 67 months). Of the 18 patients who failed 10 were treated with repeat, intensified courses. Nine patients who had recurrent tumors within 3 to 30 months after initiation of bacillus Calmette-Guerin therapy (median 6 months) eventually ceased having recurrence. Status free of disease in the 9 patients ranged from 25 to 90 months since the last recurrence (median 64 months). With retreatment of some of the early failures, the initial success rate of 78 per cent was increased to 89 per cent. These data support the concept that intravesical immunotherapy with bacillus Calmette-Guerin should be repeated in patients who initially appear not to respond. The data also suggest that bacillus Calmette-Guerin induces a durable beneficial response rather than simply delays eventual tumor recurrence.
1978年1月至1984年2月期间，120例浅表性膀胱肿瘤和/或原位癌患者参加了先前报道的卡介苗治疗试验。在所有接受治疗的患者中，78%对初始治疗有反应，随访时间为13至120个月（中位时间67个月）。在18例治疗失败的患者中，10例接受了重复强化疗程治疗。9例在卡介苗治疗开始后3至30个月内（中位时间6个月）出现复发肿瘤的患者最终停止复发。自上次复发以来，这9例患者无病状态持续时间为25至90个月（中位时间64个月）。通过对一些早期治疗失败的患者进行再治疗，初始成功率从78%提高到了89%。这些数据支持这样的观点，即对于最初似乎无反应的患者，应重复进行卡介苗膀胱内免疫治疗。数据还表明，卡介苗可诱导持久的有益反应，而不仅仅是延迟最终的肿瘤复发。
